Barclays set a €82.00 ($95.35) price objective on Merck KGaA (FRA:MRK) in a research note released on Monday, April 8th, Borsen Zeitung reports. The firm currently has a sell rating on the healthcare company’s stock.
Other equities research analysts have also recently issued research reports about the company. DZ Bank restated a neutral rating on shares of Merck KGaA in a research note on Tuesday, April 2nd. Kepler Capital Markets set a €110.00 ($127.91) price target on Merck KGaA and gave the stock a buy rating in a research note on Monday, April 1st. Deutsche Bank set a €93.00 ($108.14) price target on Merck KGaA and gave the stock a neutral rating in a research note on Monday, December 10th. Warburg Research set a €103.00 ($119.77) price target on Merck KGaA and gave the stock a neutral rating in a research note on Thursday, February 28th. Finally, Societe Generale set a €105.00 ($122.09) price objective on Merck KGaA and gave the stock a neutral rating in a report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the company. Merck KGaA currently has a consensus rating of Hold and an average price target of €100.95 ($117.38).
Shares of Merck KGaA stock traded up €1.02 ($1.19) during trading hours on Monday, hitting €95.88 ($111.49). 420,801 shares of the company were exchanged. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: Calculating net profit and net profit margin ratio
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.